SWM
NBIX icon

Spire Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Spire Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Buy
690
+651
+1,669% +$96.6K ﹤0.01% 936
2026
Q1 		$5.14K Hold
39
– – ﹤0.01% 1834
2025
Q4 		$5.53K Sell
39
-70
-64% -$10.1K ﹤0.01% 1894
2025
Q3 		$15.3K Sell
109
-9
-8% -$1.22K ﹤0.01% 1614
2025
Q2 		$14.8K Sell
118
-76
-39% -$8.72K ﹤0.01% 1602
2025
Q1 		$21.5K Sell
194
-2
-1% -$253 ﹤0.01% 1588
2024
Q4 		$26.8K Sell
196
-2
-1% -$247 ﹤0.01% 1523
2024
Q3 		$22.8K Hold
198
– – ﹤0.01% 1403
2024
Q2 		$27.3K Buy
198
+62
+46% +$8.5K ﹤0.01% 1326
2024
Q1 		$18.8K Sell
136
-17
-11% -$2.32K ﹤0.01% 1536
2023
Q4 		$21K Buy
153
+80
+110% +$9.21K ﹤0.01% 1526
2023
Q3 		$8.21K Sell
73
-316
-81% -$33.3K ﹤0.01% 1785
2023
Q2 		$36.7K Buy
389
+10
+3% +$977 ﹤0.01% 1340
2023
Q1 		$38.4K Buy
379
+254
+203% +$26.4K ﹤0.01% 1315
2022
Q4 		$15K Buy
125
+15
+14% +$1.76K ﹤0.01% 1481
2022
Q3 		$12K Sell
110
-5
-4% -$507 ﹤0.01% 1510
2022
Q2 		$11K Buy
115
+5
+5% +$461 ﹤0.01% 1888
2022
Q1 		$10K Sell
110
-17
-13% -$1.44K ﹤0.01% 2037
2021
Q4 		$11K Sell
127
-183
-59% -$16.8K ﹤0.01% 2349
2021
Q3 		$30K Hold
310
– – ﹤0.01% 1689
2021
Q2 		$30K Sell
310
-283
-48% -$27.1K ﹤0.01% 1707
2021
Q1 		$58K Buy
+593
New +$62.2K ﹤0.01% 1653

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Spire Wealth Management's NBIX Position: Q2 2026 in Review

Spire Wealth Management increased its Neurocrine Biosciences (NBIX) stake by 1,669% in Q2 2026, buying an estimated $96.6K and bringing the position to 690 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #936.

Spire Wealth Management first reported a position in NBIX in Q1 2021 and has held it in 22 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Spire Wealth Management held 690 shares of Neurocrine Biosciences worth $116K as of Q2 2026.
  • Spire Wealth Management bought 651 Neurocrine Biosciences shares in Q2 2026, an estimated $96.6K.
  • Neurocrine Biosciences made up ﹤0.01% of Spire Wealth Management's portfolio in Q2 2026, its #936 holding.
  • Spire Wealth Management first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 22 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.